Myriad Genetics, Inc. - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended December 31, 2002. Myriad Genetics, Inc. is a biopharmaceutical company operating two primary segments: Research (gene discovery, sequencing, and therapeutic product development) and Predictive Medicine (testing for disease predisposition). The company has not yet attained profitability and maintains an accumulated deficit of $86.0 million as of the reporting date.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2002 | Six Months Ended Dec 31, 2002 |
|---|---|---|
| Total Revenues | $17,019 | $32,529 |
| Net Loss | $(6,894) | $(12,211) |
| Loss Per Share (Basic/Diluted) | $(0.27) | $(0.50) |
| Cash and Cash Equivalents | $97,027 | $97,027 (Ending Balance) |
| Net Cash Used in Operating Activities | N/A | $(27,371) |
| Net Cash Provided by Financing Activities | N/A | $58,460 |
| Predictive Medicine Gross Margin | 63% | 63% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26% for the three months and 22% for the six months ended December 31, 2002, compared to the prior year periods.
- Research Revenue: Increased 25% (three months) and 12% (six months), driven by collaborations with DuPont and Abbott Laboratories, including a $1 million milestone from Abbott.
- Predictive Medicine Revenue: Increased 28% (three months) and 35% (six months) due to increased sales and marketing efforts.
- Expense Increases:
- R&D Expenses: Rose 42% (three months) and 37% (six months) due to clinical trials for prostate cancer (Flurizan) and Alzheimer's disease, plus increased collaboration efforts.
- Selling, General & Administrative (SG&A): Rose 53% (three months) and 45% (six months), primarily attributable to a direct-to-consumer marketing campaign.
- Liquidity: Cash and marketable securities increased by $15.1 million year-over-year, largely due to a public offering of common stock in November 2002.
Guidance, Outlook, and Risks
- Capital Raise: On November 26, 2002, the company received net proceeds of $57.2 million from an underwritten offering of 3 million shares of common stock. Management believes existing resources are sufficient for operations for at least the next two years.
- Outlook: The company expects to incur losses for the next several years due to the expansion of drug discovery, clinical trials, and marketing. Flurizan (MPC-7869) is in large-scale clinical trials for prostate cancer, with an IND application submitted for Alzheimer's disease.
- Risks: Key risks include the inability to achieve commercial success for new products, delays in clinical trials, dependence on pharmaceutical collaborations, and the need for substantial future capital. Interest income decreased 49% (three months) and 53% (six months) due to declining interest rates.
- Legal Proceedings: The company is not a party to any material legal proceedings.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $27.4 million net cash used in operating activities over six months against the $97 million cash balance.
- Clinical Trial Progress: Monitor the status of the Flurizan (MPC-7869) clinical trials for prostate cancer and the Alzheimer's IND application, as these drive significant R&D costs.
- Collaboration Revenue: Assess the stability of revenue from key partners (DuPont, Abbott) and the timing of future milestone payments.
- Marketing ROI: Evaluate the effectiveness of the increased SG&A spending on the direct-to-consumer campaign in driving sustainable predictive medicine revenue growth.
- Stock Dilution: Review the impact of the recent 3 million share offering and potential future financing needs on shareholder equity.